Invesco India Mid Cap Fund

A Mid Cap Fund scheme from Invesco Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF205K01MV6).

NAV ₹247.0100 on 16 November 2026.

Expense ratio

Total expense ratio 0.76% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.49%, brokerage 0.06%, transaction costs 0.00%, statutory levies including GST 0.21%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year10.0%18.4%-16.7%0.160.16
3 years23.8%17.5%-20.1%0.950.90
5 years18.8%16.5%-20.1%0.710.65
10 years20.7%16.7%-34.1%0.820.73

Category rank: 1st of 29 Direct-Growth funds in Mid Cap Fund, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 99.6% of the portfolio.

  1. Max Healthcare Institute Limited — 7.86%
  2. Prestige Estates Projects Limited — 7.65%
  3. The Federal Bank Limited — 6.08%
  4. Meesho Limited — 5.28%
  5. ETERNAL LIMITED — 4.42%
  6. Manipal Health Enterprises Limited — 4.18%
  7. L&T Finance Limited — 4.15%
  8. AU Small Finance Bank Limited — 3.95%
  9. Sai Life Sciences Limited — 3.71%
  10. Global Health Limited — 3.67%

Plans

Other funds in Mid Cap Fund

All 34 funds in Mid Cap Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.